

# Curriculum vitae with track record

## Personal information

First name, Surname:	Hans Petter Eikesdal		
Date of birth:	020672	Sex:	Male
Nationality:	Norwegian		
Researcher unique identifier:	ORCID: 0000-0003-4086-0147		
URL for personal website:	<a href="https://www.uib.no/en/persons/Hans.Petter.Eikesdal">https://www.uib.no/en/persons/Hans.Petter.Eikesdal</a>		

## Education

Year	Faculty/department - University/institution - Country
2002	PhD: Disputation date 28.05.2002. Faculty of Medicine/Institute of Medicine, Section of Oncology (PhD supervisor: Prof. Olav Dahl), University of Bergen (UIB), Norway
1997	Master: M.D. degree, Faculty of Medicine, UIB, Norway

## Positions - current and previous

Year	Job title – Employer - Country
2011-	Consultant medical & radiation oncologist (50% position), Dept. of Oncology, Haukeland University Hospital (HUH), Bergen, Norway.
2011-	Senior researcher (50% position), Bergen Breast Cancer Group, Mohn Cancer Research Laboratory, Dept. of Clinical Science, UIB, Bergen, Norway.
2019-	Professor in Oncology (20% position), Dept. of Clinical Science, Faculty of Medicine, UIB.
1998-2002	PhD Student, UIB, Norway
2001-2002	12 months Internship, Medicine & Surgery, Voss Hospital, Norway
2002-2002	6 months Internship as family practitioner, Lindaas County, Hordaland, Norway
2002-2003	Military Service as M.D., Bergen, Norway
2003-2006	Oncologist-in-training (resident), Dept. of Oncology, HUH, Norway
2006-2007	Consultant oncologist, HUH, Norway
2007-2009	Postdoctoral Fellow, Harvard University, Division of Matrix Biology, Beth Israel Deaconess Medical Center, Boston, USA
2009-2011	Consultant oncologist, HUH, Norway
2018-2018	6-months temporary position, Associate Professor in Oncology (20% position), Dept. of Clinical Science, Faculty of Medicine, UIB, Norway

## Project management experience

Year	Project owner - Project - Role - Funder
2012-2016	H.P. Eikesdal - The role PTEN pseudogene in breast cancer - Research grant for 50% researcher position - Norwegian Cancer Society
2012-2016	H.P. Eikesdal - The role of aberrant PTEN and p53 signaling in breast cancer - Project manager - Bergen Medical Research Foundation (NOK 3 300 000)
2014-2016	H.P. Eikesdal - Deregulated PI3K signaling and its relevance for chemoresistance in breast cancer - Project manager - Helse Vest (Regional Health Authority West) (NOK 1 200 000)
2014-2016	H.P. Eikesdal - The importance of PI3K signaling for chemoresistance in patients with locally advanced breast cancer - Supervisor; PhD stipend - Helse Vest
2015-2019	P.E. Lønning, H.P. Eikesdal, S. Knappskog - PErsonalized TREatment of high-risk MAMmary Cancer (PETREMAC) clinical trial. Project managers - Helse Vest (NOK 15 000 000)
2018-2022	H.P. Eikesdal - Targeted therapy of triple negative breast cancer - from lab to patient care. Research grant for 50% clinical researcher position - Helse Vest

2020-2021	H.P. Eikesdal - Predictive biomarkers to identify responders to palbociclib. Project manager - Pfizer (NOK 4 500 000)
2018-2022	P.E. Lønning, H.P. Eikesdal, S. Knappskog - K.G. Jebsen Centre for Genome-Directed Therapy in Cancer. Center PI: P.E. Lønning, Deputy leaders H.P. Eikesdal, S. Knappskog - K.G. Jebsen Foundation (NOK 18 000 000)
2020-2020	H.P. Eikesdal, T. Aas - Genomic analyses of hormone receptor positive breast cancers. Grieg Foundation (NOK 500 000)
2021-2023	H.P. Eikesdal - Identifying genomic alterations predicting response to neoadjuvant endocrine therapy. Project manager - Helse Vest (NOK 3 750 000)

### Supervision of students

Master's students	Ph.D. students	University/institution - Country
3	6	Post doctors: 1 (0 completed, 1 ongoing; 1 as main supervisor) PhD: 6 (4 completed; 1 as main supervisor, 2 ongoing; 1 as main supervisor) Master students (MD): 3 (3 completed; 3 as main supervisor, 0 ongoing)

### Other relevant professional experiences

Year	Description - Role
1998-2000	<b>Teaching:</b> Lecture series in General diseases - Diakonissehjemmet, Betanien and Bergen University Colleges, Bachelor of Nursing - Teacher
2010-ongoing	Annual national course in Tumor Biology for oncologists-in-training by the Norwegian Medical Association & UIB (Norway) - Course Administrator and teacher
2012-ongoing	Lecture series in General oncology for MD students - Faculty of Medicine, UIB (Norway) - Teacher (Professor from 2019)
	<b>Organization of scientific meetings:</b>
2001	AstraZeneca-sponsored national meeting; Advanced cancer therapy, 150 participants, Oslo, Norway - Member of Organizing committee
2013	Amgen-sponsored Nordic meeting; Improving Quality of Supportive Care in Cancer, 50 participants, Stockholm, Sweden - Member of Organizing Committee
2012-ongoing	Tema Mamma, annual, regional breast cancer meeting for Western Norway, 80 participants, Bergen, Norway - Chairman of Organizing committee
2015	Annual Meeting on Supportive Care in Cancer (MASCC/ISOO), 1700 participants, Copenhagen, Denmark - Member of Expert Faculty, scientific committee & session chair
2015	The 7 <sup>th</sup> Cancer Crosslinks meeting, 200 participants Oslo, Norway - Member of scientific committee
2016-2018	Oncology Forum, annual national meeting, 500 participants, Norway - Board member/Member of scientific committee
2020	The 12 <sup>th</sup> Cancer Crosslinks meeting, 200 participants Oslo, Norway - Chairman
	<b>Institutional responsibilities:</b>
2009	Member of PhD committee (1 <sup>st</sup> opponent), S.L. Hokland, University of Aarhus, Denmark
2012	Member of PhD committee (committee leader), B.S. Erikstein, UIB, Norway
2017	Member of PhD committee (2 <sup>nd</sup> opponent), K. Krüger, UIB, Norway
2018	Member of PhD committee (2 <sup>nd</sup> opponent), C.A. Jensen, NTNU, Norway
2020	Member of PhD committee (committee leader), M. Pilskog, UIB, Norway
2020	Member of PhD committee (2 <sup>nd</sup> opponent), J. Smeby UIO, Norway
2018	External reviewer: scientific essay for compulsory part of PhD degree, PhD candidate K.B. Hagen, Dept. of Clinical Medicine, UIB, Norway
2017-2020	Member of committees for midterm PhD evaluation, T.H. Anderson Tvedt (2017), K. Hestetun (2020), Dept. of Clinical Science, and H. Aase, Dept. of Clinical Medicine (2019), UIB, Norway

2013	External examiner for evaluation of master's theses, S.E. Dorraji, Dept. of Biomedicine, UIB, Norway
2017, 2018	Member of committees for scientific job applications, researcher (2017), Dept. of Biomedicine, and researcher (2018), Dept. of Clinical Medicine, UIB, Norway
	<b>Commissions of trust:</b>
	<u>Reviewer, Grant evaluation committees:</u>
2013-2020	French Angiogenesis Programme (Atip-Avenir, INSERM) (2013), Norwegian Cancer Society (clinical cancer research) (2014-15), Vienna Science and Technology Fund (2018), OPUS-18, National Science Center Poland (NCN panel NZ5) (2020)
	<u>Advisory Board Member:</u>
2013-2019	Nordic advisory boards: Amgen, Astra Zeneca, BMS, GSK, MSD, Novartis, Pfizer
2017-2020	European Advisory boards: Pfizer, Eli Lilly, Novartis, TLC Biopharma., Daiichi Sankyo
2015-2019	Global advisory boards: Pfizer
	<u>Principal investigator (PI)/co-investigator (co-PI), clinical trials:</u>
2003-2004	PI, Amgen trial 20030231 (all cancer, phase 3), Dept. of Oncology, HUH.
2014-2020	PI and national coordinator, Novartis trial MONALEESA-2 (breast cancer (BC), phase 3)
2012-2017	PI and national coordinator, AbbVie BC trials M12-895 (phase 2) and M12-914 (phase 3)
2016-2018	PI and national coordinator, researcher-initiated multicenter, national PETREMAC trial, NCT02624973 (BC, phase 2)
2016-ongoing	PI and national coordinator, researcher-initiated multicenter, national p53 trial, NCT02965950 (BC, phase 2)
2020-ongoing	PI and national coordinator, Pfizer Trazimera trial B3271014 (BC, phase 4)
2005-2011	Co-PI, researcher-initiated bevacizumab trial, NCT00139360 (melanoma, phase 2, 2005-11), BMS trial CA184-EAP (melanoma, phase 4, 2011-12), Roche trial MO25515 (melanoma, phase 4, 2011-12), Novartis trial BELLE-3 (BC, phase 3, 2013-17)
	<u>Member of boards &amp; steering committees; national oncology organizations and trials:</u>
2012-ongoing	Elected member, Steering Committee, Norwegian Breast Cancer Group
2016-ongoing	Elected member, Executive Committee, Norwegian Breast Cancer Group
2012-ongoing	Elected member, Reference Group, Norwegian Breast Cancer Registry
2013-2016	Elected member, Board of Representatives, The Norwegian Cancer Society
2016-2018	Elected Board Member, Oncology Forum (Onkologisk Forum), Norway
2018-ongoing	Member, Data and Safety Monitoring Board, To-Be trial, Dept. of Mammography Screening, Cancer Registry of Norway
2019-ongoing	Member, Data Monitoring Committee, PRADA2 trial, Akershus Hospital, Norway
	<u>Referee work and member of editorial boards for medical journals:</u>
2010-ongoing	Acta Oncol (member of editorial board, 2018-ongoing), Fibrogenesis & Tissue Repair (2010), J of Oncology (2013), Technology in Cancer Research and Treatment (2014), African Journal of Pharmacy and Pharmacology (2014), Tumor Biology (2014, 2016), Expert Opin Ther Targets (2014), Expert Opin Invest Drugs (2015), Anal Biochem (2015), Life Sciences (2016), Oncotarget (2016/2017/2018), Mol Cancer Ther (2017), Scientific Reports (2017), Cancer Biomarkers (2017), Int J Cancer (2017, 2018, 2020), Clin Cancer Res (2018), Epigenomics (2018), Molecular Carcinogenesis (2018), Cancer Res (2018), Cancer Medicine (2018), Expert Opin Pharmacother (2018), Cellular Physiology and Biochemistry (2018), Epigenetics (2019), The Breast (2019/20), Cancer Management and Research (2019), Eur J Gynaecol Oncol (2020).
	<u>Union work:</u>
2015-ongoing	Elected representative for The Norwegian Medical Association, for medical & radiation oncologists at the Dept. of Oncology, HUH, Norway.
	<b>Memberships of scientific societies:</b>
1991-ongoing	Norwegian Medical Association
2003-ongoing	Norwegian Oncology Association
2012-ongoing	American Society for Clinical Oncology
2012-ongoing	American Association for Cancer Research
2020-ongoing	European Society for Medical Oncology (ESMO)

	<b>Major collaborations:</b>
2007-ongoing	Professor Raghu Kalluri, Dept. of Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA. Topic: Cancer biology research.
2009-ongoing	Professors Per Eystein Lønning and Stian Knappskog, Dept. of Clinical Science, UIB, Norway. Topic: Breast cancer research.
2016-ongoing	Professor Emiel Janssen, Dept. of Pathology, Stavanger University Hospital, Norway. Topic: Breast cancer research.
2016-ongoing	Professor Tone Frost Bathen, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. Topic: Breast cancer MRI/PET-MRI research.
2019-ongoing	Dr. Violeta Serra, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Topic: Breast cancer DNA damage repair research.
2019-ongoing	Professor Mitch Dowsett, Inst. of Cancer Research, Royal Marsden Hospital, London, UK. Topic: Endocrine therapy in breast cancer

## Track record

A. The total number of publications during the career (Pubmed): 32. ISI WoS (date: 290121): H-index: 14.

B. List of ten most significant publications:

- 1) **Eikesdal HP**, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, Kalluri R. Identification of amino acids essential for the anti-angiogenic activity of tumstatin and its use in combination anti-tumor therapy. *Proc Natl Acad Sci U S A* 2008; 105(39): 15040-15045.
- 2) **Eikesdal HP**, Kalluri R. Drug resistance associated with antiangiogenesis therapy. *Semin Cancer Biol.* 2009; 19(5):310-7.
- 3) Lonning PE, **Eikesdal HP**. Aromatase inhibition 2013; clinical state of the art and questions that remain to be solved. *Endocr Relat Cancer.* 2013; 20(4): R183-201.
- 4) **Eikesdal HP**, Knappskog S, Aas T, Lonning PE. Impact of TP53 status on long-term survival in patients with locally advanced breast cancer treated with conventional anthracycline- or mitomycin-containing chemotherapy. *Acta Oncol.* 2014;53(10):1-9.
- 5) Steinskog ES, Sagstad SJ, Wagner M, Karlsen TV, Yang N, Markhus CE, Yndestad S, Wiig H, **Eikesdal HP**. Impaired lymphatic function accelerates cancer growth. *Oncotarget.* 2016;7(29):45789-45802.
- 6) Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski, TF, Alitalo K, **Eikesdal HP**, Wiig H, Swartz MA. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. *J Clin Invest.* 2016;126(9):3389-3402.
- 7) Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lonning PE, **Eikesdal HP**. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. *Breast Cancer Res Treat.* 2017;163(1):177-190.
- 8) Yndestad S, Austreid E, Skaftnesmo KO, Lonning PE, **Eikesdal HP**. Divergent Activity of Pseudogene PTENP1 in ER-positive and negative Breast Cancer. *Mol Cancer Res.* 2018;16(1):78-89.
- 9) **Eikesdal HP**, Becker LM, Teng Y, Kizu A, Carstens JL, Kanasaki K, Sugimoto H, LeBleu VS, Kalluri R. BMP7 Signaling in TGFβ Receptor-2 deficient Stromal Cells Provokes Epithelial Carcinogenesis. *Mol Cancer Res.* 2018; 16 (10):1568-1578.
- 10) **Eikesdal HP**, Yndestad S, Elzawahry A et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Ann Oncol.* 2021;32:240-249.

C. Invited presentations to peer-reviewed, internationally established conferences:

Li Fraumeni workshop, 39<sup>th</sup> Plenary meeting, Scandinavian Sarcoma Group, 8/5-19, Bergen, Norway.

D. Organisation of international conferences in the field of the applicant:

Member of Expert Faculty, scientific committee and session chair for the 2015 Annual Meeting on Supportive Care in Cancer (MASCC/ISOO), 1700 participants, Copenhagen, Denmark.

E. Prizes and Awards: Fulbright scholarship 2007-08, Harvard University, Boston, USA.